{"id":"NCT00163189","sponsor":"Pfizer","briefTitle":"Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm","officialTitle":"Evolution Of Growth Rate In Children With Growth Retardation Related To Long-term Corticotherapy And Treated By Genotonorm","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-01","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2005-09-13","resultsPosted":"2015-06-25","lastUpdate":"2024-02-21"},"enrollment":98,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Growth Hormone Deficiency"],"interventions":[{"type":"DRUG","name":"Somatropin","otherNames":[]}],"arms":[{"label":"Somatropin","type":"EXPERIMENTAL"}],"summary":"To estimate the evolution of height and growth rate over 5 years of growth hormone (GH) treatment To estimate the prognostic factors of growth rate with GH treatment To confirm the good clinical and biological safety of GH treatment in such children","primaryOutcome":{"measure":"Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36: Full Analysis Population","timeFrame":"Baseline, Month 36","effectByArm":[{"arm":"Genotonorm","deltaMin":-2.91,"sd":1.19}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":19,"countries":["France"]},"refs":{"pmids":["30910221"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6281271&StudyName=Evolution%20Of%20Growth%20Rate%20In%20Children%20With%20Growth%20Retardation%20due%20to%20Glucocorticosteroid%20Therapy%20And%20Treated%20By%20Genotonorm"]},"adverseEventsSummary":{"seriousAny":{"events":45,"n":98},"commonTop":["Insulin-like growth factor increased","Nephrotic syndrome","Diarrhoea","Arthralgia","Bronchitis"]}}